OCUL Stock — Ocular Therapeutix Inc.: Cash, EV, Pipeline

Share price

$9.99

Market cap

$2,194.0M

Cash

$598.6M

Enterprise value

$1,595.4M

Balance sheet

Cash	$598.6M
Debt	$0.0M
Net cash	$598.6M
Enterprise value	$1,595.4M
Basic shares	219.6M shares
Fully diluted shares	246.6M shares
Fully diluted market cap	$2,463.8M
Cash per share	$2.73

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading OCUL daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 19 - Apr 2	OTX-TKI	Phase 3	Neovascular Age-related Macular Degeneration	—
Sep 12 - Oct 24	OTX-TKI	Phase 3	Neovascular Age-Related Macular Degeneration (nAMD)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

DEXTENZA

Approved · Active Modality: dexamethasone intracanalicular insert (ELUTYX hydrogel)

Partnerships AffaMed (development/commercialization in mainland China, Taiwan, Hong Kong, Macau, South Korea, ASEAN)

Indications

ocular inflammation and pain following ophthalmic surgery (Approved)
ocular itching associated with allergic conjunctivitis (Approved)

Status note Commercial product.

AXPAXLI

Phase 3 · Active Modality: axitinib intravitreal hydrogel (ELUTYX)

Aliases OTX-TKI

Target tyrosine kinases (multi-target)

Indications

wet age-related macular degeneration (wet AMD) (Phase 3)
non-proliferative diabetic retinopathy (NPDR) (Phase 3)

Status note SOL-1 Phase 3 (wet AMD) with SOL-R repeat-dosing and SOL-X extension studies; HELIOS-3 Phase 3 (NPDR); NDA planned on SOL-1 Week 52 data.

OTX-TIC

Phase 2 · Active Modality: travoprost intracameral hydrogel (ELUTYX)

Target FP receptor

Partnerships AffaMed (development/commercialization in mainland China, Taiwan, Hong Kong, Macau, South Korea, ASEAN)

Indications

open-angle glaucoma (Phase 2)
ocular hypertension (Phase 2)

Status note Phase 2 completed; next steps being determined; no discontinuation disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	OTX-TKI
Lead indication	Neovascular Age-related Macular Degeneration
Lead phase	Phase 3
Active trials	4
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06495918	Phase 3	Active, not recruiting	Sponsor	OCUL	—	Neovascular Age-related Macular Degeneration	—
NCT07235085	Phase 3	Recruiting	Sponsor	OCUL	—	Non-Proliferative Diabetic Retinopathy	—
NCT07516132	Phase 3	Recruiting	Sponsor	OCUL	—	Neovascular Age-Related Macular Degeneration (nAMD)	—
NCT06223958	Phase 3	Active, not recruiting	Sponsor	OCUL	—	Neovascular Age-Related Macular Degeneration	—
NCT04371445	Not disclosed	Recruiting	Collaborator	The Cleveland Clinic	—	Vitreoretinal Surgery; Ocular Inflammation; Post-operative Pain	—
NCT04205916	Not disclosed	Recruiting	Collaborator	Ophthalmic Consultants of Long Island	—	Patient Preference	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for Ocular Therapeutix, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Logos Global Management	5,300,000	+1,450,000	2.24%	2026-08-14
OrbiMed Advisors	220,000	+220,000	0.04%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

OCUL — Ocular Therapeutix Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders